Keyword: Merck

Merck paired up with Foundation Medicine to develop a pan-cancer diagnostic for Keytruda to measure microsatellite instability and other biomarkers.

Raising the cash sets Strata up to file for approval of a tumor molecular profiling assay while building out its platform.

PPD and its real-world data unit Evidera will be the first CRO to join MIT’s biotech think tank, starting with an evidence generation pilot project.

ImmusanT recently expanded its senior staff, bringing on Daiichi Sankyo’s senior VP for internal medicine, Ken Truitt, as its chief medical officer.

Johnson & Johnson unit Janssen joins the Alzheimer's failure club after deciding to stop trials of its BACE inhibitor atabacestat.

Seattle Genetics names Keytruda developer as CMO and Aravive CEO Stephen Eck leaves to join Immatics.

Seattle Genetics appointed Roger Dansey as CMO, who led Merck’s late-stage oncology work, including developing Keytruda in multiple tumor types.

Syndax’s entinostat-Keytruda combination may have posted small gains in NSCLC, but an enrichment biomarker could predict increased clinical benefit.

Roche is axing its IDO/TDO inhibitor work “in its entirety” with partner NewLink Genetics.

Merck and OncoSec partnered on a second immunotherapy combination, now in triple-negative breast cancer, following a melanoma study last year.